

Curasight A/S announces its intention to carry out a directed issue of shares

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION WHERE THIS PRESS RELEASE IS DISTRIBUTABLE WOULD BE ILLEGAL OR REQUIRE ADDITIONAL ACTIONS THAN SUCH ACTIONS RESULTING FROM DANISH LAW. SEE THE "IMPORTANT INFORMATION" SECTION AT THE END OF THIS PRESS RELEASE.

Curasight A/S ("Curasight" or the "Company" – TICKER: CURAS) hereby announces its intention to carry out a directed issue of shares of a minimum of approximately DKK 18 million through an accelerated book-building procedure (the "Directed Issue"). Curasight recently reported encouraging interim data from its Phase I uTREAT[®] study. Following these results, the Company intends to carry out the Directed Issue intended to strengthen its working capital and support the continued clinical development of uTRACE[®] and uTREAT[®] through the end of H1 2027. In connection with the Directed Issue, the Company also intends to renegotiate the outstanding loan from Fenja Capital II A/S ("Fenja Capital", the "Lender").

The shares will be offered exclusively to qualified investors by way of an accelerated bookbuilding process. The Directed Share Issue will be initiated immediately after publication of this announcement and may be terminated at short notice. The Company has appointed Sedermera Corporate Finance ("Sedermera") as sole global coordinator and sole bookrunner.

The Directed Issue

The Board of Directors has today resolved to evaluate the possibility of carrying out a directed issue of a minimum of DKK 18 million to institutional and professional investors, pursuant to the authorization granted by the general meeting and as stated in article 5.1.2 of the Company's articles of association. The price of the new shares in the Directed Issue (the "Subscription Price") will be determined through an accelerated bookbuilding procedure, which will commence immediately following the publication of this press release and end before commencement of trading on Spotlight Stock Market on 23 June 2026. The timing of the completion of the bookbuilding process, pricing and allocation is determined at the discretion of the Company and may be shortened, extended or interrupted at any time, which means that the Company may fully or partially refrain from carrying out the Directed Issue.

Prior to the Directed Issue, the Company's Board of Directors has made an overall assessment and carefully considered the possibility of raising capital through a rights issue. The Board of Directors considers that the reasons for deviating from the shareholders' pre-emption right are (i) that a rights issue would take a significantly longer time to complete and entail a higher risk for a material adverse effect on the share price, (ii) to diversify and strengthen the Company's shareholder base with Nordic, international, institutional and professional investors, and to strengthen the share's liquidity, (iii) carrying out a directed share issue can be made at lower costs and with less complexity than a rights issue and, the Board of Directors has assessed that a rights issue would also entail a risk of not being fully subscribed or necessitate significant underwriting commitments and (iv) to ensure a strong balance sheet. Considering the above, the Board of Directors has made the assessment the Directed Issue with deviation from the shareholders' pre-emptive right is the most favorable alternative for Curasight.

By establishing the Subscription Price in the Directed Issue through an accelerated bookbuilding procedure, it is the assessment of the Board of Directors that the subscription price will be determined on market terms.

Loan Facility

In connection with the Directed Issue, the Company intends to renegotiate the outstanding loan facility with Fenja Capital. The loan facility was secured in December 2025 and amounted to DKK 40 million, structured in two tranches. The first tranche of DKK 25 million, structured as a convertible loan, was drawn in connection with the directed share issue completed in December 2025. In March 2026, Fenja Capital converted part of the loan, and as of today, the outstanding amount under the first tranche totals approximately DKK 20.7 million. During Q2 2026, the Company has also drawn the second and final tranche of the facility, amounting to DKK 15 million. Accordingly, the total outstanding loan amounts to approximately DKK 35.7 million (the "Total Outstanding Loan").

Following the renegotiation, the maturity date for the Total Outstanding Loan from Fenja Capital intends to be extended from 29 December 2026 to 30 June 2027.

Advisors

Sedermera Corporate Finance AB acts as Sole Global Coordinator and bookrunner in connection with the Directed Issue. DLA Piper is the Company's legal advisor.

For more information about the Directed Issue, please contact:

Sedermera Corporate Finance AB

Phone: +46 (0)40 615 14 10

E-mail: cf@sedermera.se

www.sedermera.se

For further information about the Company, please contact:

Ulrich Krasilnikoff, CEO, Curasight A/S

Phone: +45 22 83 01 60

E-mail: uk@curasight.com

www.curasight.com

Important information

The publication, release or distribution of this press release may be restricted in certain jurisdictions. Recipients of this press release in jurisdictions where this press release has been published or distributed should inform themselves about and observe any such restrictions. This announcement does not constitute an offer to the public, or a solicitation of any offer, to buy or subscribe for any securities of the Company in any jurisdiction. This document has not been approved by any authority in any jurisdiction and does not constitute a prospectus within the meaning of Regulation (EU) 2017/1129 (the "Prospectus Regulation"). No prospectus has been or will be prepared in connection with the Directed Issue. In any EEA Member State, this communication is only addressed to and is only directed at "qualified investors" in that Member State within the meaning of the Prospectus Regulation.

The information contained in this press release is for background purposes only and does not purport to be full or complete. No reliance may or should be placed by any person for any purpose on the information contained herein or its accuracy or completeness. Neither the Company nor any of its affiliates, advisors or representatives accepts any responsibility or liability whatsoever for, or makes any representation or warranty, express or implied, as to the truth, accuracy or completeness of the information in this press release (or whether any information has been omitted).

The information in this press release may not be announced, published, copied or distributed, directly or indirectly, in the United States, Canada, Japan, Australia, Hong Kong, New Zealand, Singapore, Belarus, Russia, South Africa or any other jurisdiction where the announcement, publication or distribution of the information would not comply with applicable laws and regulations or would require a prospectus, registration or other measures than those required by Danish law.

This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States absent registration or an applicable exemption from, or in a transaction not subject to, registration under the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of such securities in the United States.

This announcement does not constitute an invitation to underwrite, subscribe for or otherwise acquire or dispose of any securities in any jurisdiction. This press release does not constitute a recommendation for any investor's decision regarding the Directed Issue. Each investor or potential investor should conduct its own investigation, analysis and evaluation of the business and information described in this press release and any publicly available information. The price and value of the securities may go down as well as up and past performance is no guide to future results. Neither the contents of the Company's website nor any other website accessible through hyperlinks on the Company's website are incorporated into or form part of this press release.

Forward-looking statements

This press release contains forward-looking statements that reflect the Company's intentions, beliefs or expectations regarding the Company's future results of operations, financial condition, liquidity, performance, prospects, anticipated growth, strategies and opportunities and the markets in which the Company operates. Forward-looking statements are statements that are not historical facts and can be identified by the use of words such as "believes", "expects", "anticipates", "intends", "estimates", "will", "may", "anticipates", "should", "could" and, in each case, the negatives thereof, or similar expressions. The forward-looking statements in this press release are based on various assumptions, many of which are based on additional assumptions. Although the Company believes that the assumptions reflected in these forward-looking statements are reasonable, there can be no assurance that they will materialize or that they are accurate. Because these statements are based on assumptions or estimates and are subject to risks and uncertainties, actual results or outcomes could differ materially from those in the forward-looking statements for a variety of reasons. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this press release by the forward-looking statements. The Company does not guarantee that the assumptions underlying the forward-looking statements contained in this press release are accurate and any reader of this press release should not place undue reliance on the forward-looking statements contained in this press release. The information, opinions and forward-looking statements expressed or implied herein are made only as of the date of this press release and may be subject to change.

About Curasight

Curasight is a clinical stage radiopharmaceutical company developing a first-in-class uPAR-targeted theranostic system for aggressive solid tumors. Its radioligand therapy uTREAT® is paired with uTRACE® (uPAR PET imaging) using the same ligand for patient selection and confirmation of tumor targeting; uTRACE® has been evaluated in more than 450 patients across eight solid tumor types.

Curasight is also advancing next-generation uPAR-targeting ligands designed for modular alpha- and beta-emitting radionuclide payloads and substantially higher binding affinity, with the aim of supporting expansion into a broader range aggressive solid tumors. Curasight is based in Denmark and listed on the Spotlight Stock Market (ticker: CURAS).

This disclosure contains information that Curasight is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 22-06-2026 18:43 CET.